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Materials and Methods Table S1 . Oligonucleotide sequences used in this study. >50kDa, 5) 10-50kDa and 6) <10kDa. All the fractions were reconstituted with the essential growth factors and 2% Matrigel and applied to MCF7 or MCF10A cells seeded at 5000 cells/well in Matrigel-coated 8-well chamber slides. The collection/application of CM was performed every 12~15hrs for 1 week. To determine when differentiating MECs produce cytotoxic factors, the 10-50kDa fraction of CM was harvested at each day (days 0-6) from differentiating MCF10A in 3D lrECM using the above-mentioned condition. Different day fractions were individually applied to MCF7 cells plated at 1000 cells/well in Matrigel-coated 96-well plate. Fresh CM was applied every 24hrs. For cell number counting, cells were recovered from Matrigel after 1 week by digestion with dispase (BD Biosciences), and the viable cell numbers were measured using trypan blue exclusion method.
Sample preparation for mass spectrometric analysis
The cytotoxic fraction (10-50kDa, day 4) of CM from differentiating MCF10A cells and the soluble fraction of CM from MCF7 cells in 3-D laminin-rich ECM gels (day 4) were collected.
Proteins in each medium were concentrated by trichloroacetic acid (TCA) precipitation and dissolved in boiling SDS sample buffer. Proteins were resolved by SDS-PAGE (10%) and visualized with Coomassie Blue staining. Gel slices (2mm thickness) were excised, de-stained with 25mM NH 4 HCO 3 in 50% MeOH and digested with 50ng/ml trypsin in 50mM NH 4 HCO 3 for 24 h at 37 °C. Peptides were extracted from gel slices with 3 volume of 50% acetonitrile, vacuum-dried and resuspended in 0.1% formic acid. Following sample clean up in C18 ZipTips (Millipore), peptides were eluted with 0.1% formic acid in 50% acetonitrile.
Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS)
The cytotoxic fraction (10-50kDa, day 4) of CM from differentiating MCF10A cells and the soluble fraction of CM from MCF7 cells in 3D matrix (day 4) were analyzed for LC-MS/MS spectrometry as described (3, 4) . For LC-MS/MS analysis, the digests were first separated by cation exchange chromatography (polysulfoethyl A column, Nest Group) using a linear gradient between solvents A (5mM KH 2 PO 4 , 30% acetonitrile, pH 3) and B (solvent A with 350mM KCl) at a flow rate of 0.2 ml/min. Fractions were collected on the basis of UV absorbance (215 and 280nm) and desalted with C18 micro spin columns (Vivascience). LC-MS/MS was carried out by nanoflow reverse phase liquid chromatography (RPLC) (Ultimate LC Packings) coupled online to QSTAR XL tandem mass spectrometer (Applied Biosystems). RPLC was performed using a capillary column (75µm x 150mm) packed with Polaris C18-A resin (Varian Inc.), and the peptides were eluted using a linear gradient between solvents A (2% acetonitrile, 0.1% formic acid) and B (98% acetonitrile, 0.1% formic acid) at a flow rate of 250 nl/min. Each full MS scan was followed by three MS/MS scans where three most abundant peptide ions were selected to generate tandem mass spectra. Two LC-MS/MS runs were performed on the same sample to improve the dynamic range of mass spectrometric analysis.
Protein identification
For MS data analysis, monoisotopic masses (m/z) of peptide ions were obtained from the tandem mass spectra using Mascot script in Analyst QS version 1.1 software (Applied Biosystems) with the mass accuracy of ±200ppm. Certain chemical modifications (i.e., N-terminal acetylation or pyroglutamine, methionine oxidation, asparagine deamination, carbamylation of the N-terminus and lysine, phosphorylations of serine, threonine and tyrosine) were selected as variables during and discriminating score <6 were considered significant.
Immunodepletion
The cytotoxic fraction (10-50kDa, days 3-5) of CM was harvested from differentiating MCF10A Table. S1 and western analysis of secreted proteins in the conditioned media. For determining the cytotoxic activity of each factor, 7ml of CM from 293T cells (4x10 6 ) was harvested, concentrated by 2 fold with Centricon-10 and normalized based on the total protein amount. The media were supplemented with growth factors plus 2% Matrigel and applied to MCF7 cells seeded at 5000 cells/well in Matrigel-coated 8-well chamber slides. Fresh CM was applied every 24 hrs for one week, and the viable cell numbers were counted. To generate a stable cell line for IL-25 purification, IL-25 cDNA was subcloned into BamHI site of pQCXIH retroviral vector (BD Biosciences). GP 2 -293 packaging cells were transfected with pQCXIH/IL25 and pVSVG plasmids using Lipofectin, and retrovirus was harvested in the conditioned medium. 293T cells were infected with retrovirus using 8µg/ml polybrene, and the stable clones were selected with 70 µg/ml Hygromycin B (Roche). IL-25 retrovirus was generated to establish a stable 293T cell line as described (5).
Purification of secreted IL-25 by concanavalin A column followed by gel filtration column
CM was collected from a stable 293T cell line expressing IL-25, supplemented with protease inhibitors and loaded onto a column packed with concanavalin A-sepharose beads (CalBiochem) pre-equilibrated with column buffer (10mM Tris (pH7.5), 150mM NaCl, 1mM CaCl 2 , 1mM
MnCl 2 ). The column was washed with column buffer, and bound glycosylated proteins were eluted with 0.5M α-methyl mannose in column buffer. The eluates were pooled, concentrated with Centricon-10 and then separated by Superdex 200 gel filtration column (HR 10/30, 24mL;
Amersham Pharmacia) using elution buffer (50mM Na 2 HPO 4 (pH7.5), 50mM NaCl) at a flow rate of 0.4ml/min. Fractions were collected based on UV absorbance at 280nm and resolved on 10% SDS-PAGE for western analysis.
Purification of secreted IL-25 by indirect immunoaffinity chromatography
The IL-25 antibody was indirectly conjugated with agarose beads as follows. 1 mg of IL-25
antibody was dissolved in 2ml PBS and incubated with 1ml slurry of protein G-agarose (~50%) for 1h at RT. Beads were washed in 5ml sodium borate (0.2M, pH 9.0), resuspended in 5ml 
Colony formation assay
Breast cancer cells (MCF7, MDA-MB468, SKBR3 and T47D) at 1000/well and MCF10A cells at 500/well were seeded in 6-well plates in triplicate and maintained for 24hrs. Designated amounts of IL-25 were diluted in elution buffer to 100µl and then in 900µl growth medium to culture cells. After 10 days cells were stained with 2% Methylene Blue in 50% EtOH, and the numbers of colonies were counted.
Tumor inhibition assay in nude mice
Animal experiments were performed under federal guidelines and approved by Institutional Animal Care and Use Committee at UCI. Exponentially growing MDA-MB-468 cells at 10x10 6 in 100µl of DMEM plus 5% Matrigel were injected into the mammary fat pad of 6-8 week old athymic female BALB/c-nude mice (nu/nu) (Charles River Laboratories). After tumors grew to 80mm 3 (day 10), mice were randomized into control (n=7) and experimental groups (n=8) to receive on site injection of vehicle (elution buffer, 50µl) or IL-25 (300ng, 50µl) once every day for 31 days. Mouse body weights and tumor volumes were measured twice weekly. Student's t test was used to determine p-value as indicated in the figure legend. At the end of experiments, mice were sacrificed and subjected to pathological examinations of different organs, including intestines, kidney, heart, lungs, liver and stomach, to test the presence of systemic inflammation.
Tumor xenografts were excised for histological examinations. For the safety test, IL-25 (1.5µg) was injected into the tail veins of female C57 mice (vehicle: n=3; IL-25: n=5), and signs for systemic stress (e.g., lethargy and weight loss) were monitored daily.
Breast tumor samples
Patient cohort 1: All cases were invasive ductal carcinomas, which account for more than 90% of archived breast cancer samples in National Taiwan All tumor cases were invasive ductal carcinomas between stages II and III according to ScarfBloom-Richardson system. Normal tissues were obtained from reduction mammoplasty samples.
These tissues were provided by the Cooperative Human Tissue Network (NCI).
Histology and immunohistochemistry
Dissected tumors were fixed in 4% paraformaldehyde overnight and embedded in paraffin with a tissue processor. 4-5µm sections were deparaffinized and hydrated. Tumor xenografts were stained with hematoxylin and eosin, while human breast tumor specimens were processed for immunohistochemistry. Antigen retrieval was performed in 0.01 M citric buffer at 100°C for 10 minutes. After being blocked in 3% H 2 O 2 and nonimmune horse serum, the slides were reacted with a monoclonal antibody against human IL-25R (GeneTex CAT # GTX13653; 1:100 dilution)
at 4°C overnight and incubated with link antibodies, followed by peroxidase conjugated clone; however, our testing showed that this replacement clone did not have the same immunoreactivity as the first clone listed under the same catalog number and thus we chose not to use this second clone from GeneTex. We found that by western blot, IP, detection of IL-25R in knock-down and overexpression experiments the results obtained using the IL-25R antibody available from R&D Systems were interchangeable with those obtained using the first clone of GeneTex antibody. The only relevant difference being that the R&D antibody could not be used for IHC on paraffin-embedded sections, and that is why the IHC analysis using the R&D antibody was performed using frozen sections.
IL25R, FADD or TRADD siRNA treatment
Breast cancer cells or nonmalignant MCF10A cells were plated at 3.5x10 5 /60mm dish and maintained for 24 hrs. Cells were transfected with 400pmol of annealed siRNA for IL-25R, FADD or TRADD (Table S1 , Qiagen) using Oligofectamine (Invitrogen) according to manufacturer's instruction. Luciferase siRNA was used as a non-specific control.
Soft agar assay
One % agar was mixed with the equivalent volume of 2x DMEM plus 20% FBS and 2% penicillin/streptomycin. One ml of the agar solution was poured into a 35 mm plate in triplicate and solidified. 0.7% agar solution equilibrated to 40°C was mixed with 2x growth medium and breast cancer cells at 4000 cells/ml and poured onto the base agar at 1 ml/plate. The solidified agar was covered with 500µl growth medium and maintained in 37°C humidified incubator for 2 weeks. The plates were stained with 0.01% crystal violet for 30 min, and colonies were counted under dissecting microscope.
Immunoprecipitation
Nine mg of whole cell lysates were collected in 3ml of Triton lysis buffer (25mM Tris (pH7.6), 150mM NaCl, 1% TritonX-100) supplemented with protease and phosphatase inhibitors. The lysate was divided into three fractions (3mg protein/1ml each), and each fraction was clarified with 50µl of protein G sepharose beads at 4°C for 2hrs. Two µg of antibody against p84 (Ctrl), IL-25R or FADD (Cell Signaling) was added to each fraction and incubated at 4ºC overnight.
Antibody-protein complex was precipitated by 50µl protein A/G sepharose beads at 4°C for 2hrs
and washed in TEN buffer with 0.1% NP-40 and protease inhibitors. Immunoprecipitates were resolved on 12% SDS-PAGE and detected by western analysis.
IL25R expression constructs
The expression construct of human IL-25R in pCMV6-XL5 vector was obtained from OriGene.
The wild-type IL-25R was subjected to mutagenesis to generate a siRNA-resistant mutant (RM), a deletion mutant at TRAF6 binding domain (∆TRAF6) or death domain-like region (∆DD) by using a corresponding primer pair (Table S1 ). Correct mutagenesis was validated by sequencing.
IL17B shRNA construction. Forward and reverse oligonucleotides (see supplementary Table   S1 for the sequences) were annealed to generate a double-stranded DNA oligonucleotide, which in turn was ligated into BamH1/EcoR1 site of pGreen puro lentiviral vector (System Biosciences). For control, luciferase shRNA vector was used (System Biosciences). Lentivirus production and transduction of target cells were conducted following the guideline by the manufacturer. Briefly, lentivirus vector and packaging plasmid mix (System Biosciences) were transfected into 293FT cells (Invitrogen) using Lipofectamine® 2000. After 48 hours, medium was harvested, filtered and used to infect target cells with the addition of polybrene (10 µg/ml).
After 24 hours medium was replaced. At 72 hours post-infection puromycin (0.5 µg/ml) was added for selection and maintained throughout the culturing period.
Cell proliferation assay. Cells were plated at a density of 1 x 10 3 cells per well in 96-well plates in DMEM plus 10% FBS and incubated at 37°C. Twenty-four hours before each time point, the medium was replaced. At each time point, MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich) was added to cells to the final concentration of 1.6 mg/ml, and the reaction was incubated at 37°C for 4 hours. Then, the medium was removed and the precipitated reaction product was dissolved in MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol). The absorbance was measured at 570 nm.
Invasion assays. Cells at 2.5 X 10 4 were placed on the top of a thin Matrigel layer in 24-well invasion chamber (BD Biosciences) according to the manufacturer's protocol. After 48 hours, cells were stained with 0.2% methylene blue in 50% ethanol. Samples were prepared in triplicate and invaded cells were counted on at least 3 different fields on the trans-well filters. Statistical analysis was performed using an unpaired t-test. A p-value <0.05 was considered to be significant. Table S1 . Oligonucleotide sequences used in this study.
Supplementary data
1 Unique NdeI restriction site generated is shown in italics. 2 Unique SacI restriction site generated is shown in italics. 3 Unique NheI restriction site generated is shown in italics. 4 Nucleotides substituted without changing the encoded amino acids are shown underlined. (G) The number of colonies formed on in soft agar as in (F) were quantified and compared between control and IL-17Bsh-treated cells. ***P-value < 0.001. N=6.
(H) Ectopic addition of recombinant IL-17B protein (50 ng/ml) to the culture medium promoted the proliferation rate of MDA-MB468 cells, as determined by MTT assay. *P-value < 0.05.
N=12.
(I) Ectopic addition of recombinant IL-17B protein to the culture medium at different concentrations promoted the clonogenic potential of MDA-MB468 cells. N=6.
